Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The ongoing global pandemic of coronavirus disease 2019 (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused devastating impacts …

The newly emerged SARS-CoV-2 saltation variant, BA. 2.86, has raised global concern
(appendix 1 p 7). By Sept 8, 2023, 95 sequences were detected, of which their early …

Abstract Ever-evolving SARS-CoV-2 variants of concern (VOCs) have diminished the
effectiveness of therapeutic antibodies and vaccines. Develo** a coronavirus vaccine that …

Under pressure from neutralising antibodies induced by vaccination or infection the SARS-
CoV-2 spike gene has become a hotspot for evolutionary change, leading to the failure of all …

The emergence of Omicron lineages and descendent subvariants continues to present a
severe threat to the effectiveness of vaccines and therapeutic antibodies. We have …

The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …

Neutralizing antibodies correlate with protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). Recent studies, however, show that binding antibody titers, in …

Antigenic drift of SARS-CoV-2 is typically defined by mutations in the N-terminal domain and
receptor binding domain of spike protein. In contrast, whether antigenic drift occurs in the S2 …

The fusion peptide of SARS-CoV-2 spike protein is functionally important for membrane
fusion during virus entry and is part of a broadly neutralizing epitope. However, sequence …